Product
Invert Launches Invert AssistToday, Invert launches Invert Assist, the first AI-powered analysis interface built for bioprocess. Using a simple chat interface, Invert Assist enables users to perform complex analysis that typically takes an expert team hours to code manually. With the freedom and flexibility of natural language, bioprocess scientists can turn days or even weeks of troubleshooting and optimization into a 5-minute conversation with their data.
Industry
AI That Bioprocess Teams Can Trust: Highlights from BioTalk BerlinRecorded live at BioTalk Berlin on September 18, 2025 — featuring Michael McCutchen, Senior Product Manager at Invert. Scroll to the end to watch the full talk.
Product
Engineer Blog Series: Invert Assist with Simon Sotak GregorInvert recently launched Invert Assist, our AI interface for bioprocess data analysis. We speak to senior software engineer Simon Sotak Gregor about Invert Assist to learn more about how it was built, what problems it solves, and how he hopes it’ll change the way bioprocess is done.
Product
Engineer Blog Series: Integrations with Julia MillerSenior software engineer Julia Miller speaks to us about Invert's integrations — how they're implemented, what makes them special, and what goes into making them work for bioprocess.
Product
Invert Launches Alerts: Turning Real Time Data Into Immediate ActionInvert Alerts transform real time bioprocess data into immediate, actionable notifications so scientists can act in the moment, protect their runs, and focus on advancing processes instead of manually monitoring them
Interviews
On-Demand Webinar: The Future of Data in BioprocessingDiscover how bioprocessing data is evolving from spreadsheets to AI-driven insights. Watch the on-demand webinar to future-proof your digital strategy.
Team
Meet Emily Nault, Invert’s New SVP of CommercialInvert is excited to announce that Emily Nault has joined the company as our Senior Vice President of Commercial.
Product
Why ELNs and LIMS are not enough for PD teamsOne of the questions we’re asked frequently is whether Invert is an ELN or LIMS—our answer is that Invert captures both systems’ strengths and fixes their weaknesses. We’ll discuss the trade-offs and shortcomings of ELN and LIMS when it comes to bioprocess data to explain how.
Suhas Guruprasad, the Head of AI at Invert, dives into the evolution of artificial intelligence, distinguishing between the actual capabilities of AI and the often exaggerated hype surrounding it.
.png)
Exciting news! Invert is launching a Q&A series, Pioneers in Bioprocessing, to chat with experts in bioprocessing and biotechnology to discuss their work, the potential of the bioeconomy at large, and the personal viewpoints of the individuals who make this work possible.
The transfer of institutional data and knowledge is critical to the development of biotechnologies, bioproducts, and biotherapeutics.
For biotech and synthetic biology companies, there’s always A LOT of work to do. As these companies quickly learn, trying to handle everything in-house–from strain design and high-throughput screening to process development and beyond–can spread funding and resources thinly.
Biotech and synthetic biology companies have much to do. Handling everything in-house—from strain design to process development—can stretch funding and resources thin.
.png)